The use of different anti-PD-L1 antibodies in each of these studies (Thompson et al: clone 5H1; Hendry et al: clone SP263; this study: clone E1L3N), as well as the different definitions of PD-L1 tumor positivity, may explain these differences. This evidence concerns the gene CD274 and neoplasm.